FDA says Moderna (MRNA) exposed participants, age 65 and over, to increased risk of severe illness by giving them a sub standard of care against the recommendation of FDA career scientists

The FDA's statement regarding Moderna suggests significant regulatory scrutiny and potential reputational damage for the company, which could lead to market volatility.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

US Treasury Secretary Bessent says US growth might have come to 3% for 2025, Fox News reports; expects a continued pickup in construction jobs; sees a pickup in manufacturing jobs in the coming months

Pentagon prepares second aircraft carrier to deploy to Middle East, WSJ reports; Pentagon move comes as Trump raises pressure on Iran to make nuclear deal

FDA says Moderna (MRNA) exposed participants, age 65 and over, to increased risk of severe illness by giving them a sub standard of care against the recommendation of FDA career scientists

US Monthly Budget Statement (Jan) -95.0B vs. Exp. -86.5B (Prev. -145.0B, Rev. From -145B)

US President Trump say meeting with Israeli PM Netanyahu was very good; insisted that negotiations with Iran continue to see whether or not a deal can be consummated, which would be his preference, but if not, we will see what happens

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This development raises concerns about compliance with safety protocols, potentially impacting investor sentiment and regulatory actions against Moderna. Watch for implications on Moderna's stock performance and how this may influence broader market dynamics in the biotechnology sector.

Related headlines

The whole workspace, free to try.

Try it free